One Breath-Hold MRI could replace liver biopsies for NASH

NCT ID NCT05384652

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new MRI technique that measures liver fat, fibrosis, and inflammation in a single 14-second breath-hold, without needles or contrast dye. Researchers will scan 120 people with fatty liver disease (60 with simple steatosis and 60 with NASH) and compare results to liver biopsies. If accurate, this could offer a non-invasive way to diagnose NASH and track liver health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MRI scan (no drug or device)
What this could lead to
If successful, this could provide a fast, needle-free way to diagnose NASH and monitor liver health without a biopsy.
What could go wrong
This is an early diagnostic study, not a treatment trial. The new MRI method may not be accurate enough to replace biopsies, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Chinese University of Hong Kong, Prince of Wale Hospital

    Hong Kong, Shatin, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.